Emodin attenuates high glucose-induced TGF-β1 and fibronectin expression in mesangial cells through inhibition of NF-κB pathway

Experimental Cell Research

Volumn 319, Issue 20, 2013, Pages 3182-3189

  Yang, Jie ^a   Zeng, Zhi ^b   Wu, Teng ^b   Yang, Zhicheng ^b   Liu, Bing ^b   Lan, Tian ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Emodin; FN; High glucose; Mesangial cells; NF B; TGF 1

Indexed keywords

EMODIN; FIBRONECTIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOPLASM; DIABETIC NEPHROPATHY; DNA BINDING; KIDNEY HYPERTROPHY; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84887203488     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.10.006     Document Type: Article

References (32)

1. Mauer S.M., Steffes M.W., Ellis E.N., Sutherland D.E., Brown D.M., Goetz F.C. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 1984, 74:1143-1155.
2. Schena F.P., Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2005, 16(Suppl. 1):S30-S33.
3. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146.
4. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N. Eng. J. Med. 2000, 342:1350-1358.
5. Mogyorosi A., Kapoor A., Isono M., Kapoor S., Sharma K., Ziyadeh F.N. Utility of serum and urinary transforming growth factor-beta levels as markers of diabetic nephropathy. Nephron 2000, 86:234-235.
6. Sanz A.B., Sanchez-Nino M.D., Ramos A.M., Moreno J.A., Santamaria B., Ruiz-Ortega M., Egido J., Ortiz A. NF-kappaB in renal inflammation. J. Am. Soc. Nephrol. 2010, 21:1254-1262.
7. Navarro J.F., Mora C. Role of inflammation in diabetic complications. Nephrol. Dial. Transplant. 2005, 20:2601-2604.
8. Navarro J.F., Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. Sci. World J. 2006, 6:908-917.
9. Clavreul N., Sansilvestri-Morel P., Magard D., Verbeuren T.J., Rupin A. (Pro)renin promotes fibrosis gene expression in HEK cells through a Nox4-dependent mechanism. Am. J. Physiol. 2011, 300:F1310-F1318.
10. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. 2007, 292:F1141-F1150.
11. Li X., Liu W., Wang Q., Liu P., Deng Y., Lan T., Zhang X., Qiu B., Ning H., Huang H. Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Mol. Cell. Endocrinol. 2009, 307:157-162.
12. Liu Y., Jia L., Liu Z.C., Zhang H., Zhang P.J., Wan Q., Wang R. Emodin ameliorates high-glucose induced mesangial p38 over-activation and hypocontractility via activation of PPARgamma. Exp. Mol. Med. 2009, 41:648-655.
13. Chang C.H., Lin C.C., Yang J.J., Namba T., Hattori M. Anti-inflammatory effects of emodin from ventilago leiocarpa. Am. J. Chin. Med. 1996, 24:139-142.
14. Lan T., Liu W., Xie X., Xu S., Huang K., Peng J., Shen X., Liu P., Wang L., Xia P., Huang H. Sphingosine Kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol. Endocrinol. 2011, 25:2094-2105.
15. Li D., Zhang N., Cao Y., Zhang W., Su G., Sun Y., Liu Z., Li F., Liang D., Liu B., Guo M., Fu Y., Zhang X., Yang Z. Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-kappaB and MAPKs signal pathways. Eur. J. Pharmacol. 2013, 705:79-85.
16. Zhang W., Chen H., Liu D.L., Li H., Luo J., Zhang J.H., Li Y., Chen K.J., Tong H.F., Lin S.Z. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-kappaB and its regulated targets. Int. J. Oncol. 2013, 42:1189-1196.
17. Jiang Q., Liu P., Wu X., Liu W., Shen X., Lan T., Xu S., Peng J., Xie X., Huang H. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol. Cell. Endocrinol. 2011, 331:34-40.
18. Gennero I., Fauvel J., Nieto M., Cariven C., Gaits F., Briand-Mesange F., Chap H., Salles J.P. Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density. J. Biol. Chem. 2002, 277:12724-12734.
19. Lan T., Shen X., Liu P., Liu W., Xu S., Xie X., Jiang Q., Li W., Huang H. Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway. Arch. Biochem. Biophys. 2010, 502:112-120.
20. Abraham S., Sweet T., Khalili K., Sawaya B.E., Amini S. Evidence for activation of the TGF-beta1 promoter by C/EBPbeta and its modulation by Smads. J. Interferon Cytokine Res. 2009, 29:1-7.
21. Stanisavljevic J., Porta-de-la-Riva M., Batlle R., de Herreros A.G., Baulida J. The p65 subunit of NF-kappaB and PARP1 assist Snail1 in activating fibronectin transcription. J. Cell Sci. 2011, 124:4161-4171.
22. Ichinose K., Kawasaki E., Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am. J. Nephrol. 2007, 27:554-564.
23. Zhang S.L., Filep J.G., Hohman T.C., Tang S.S., Ingelfinger J.R., Chan J.S. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int. 1999, 55:454-464.
24. Guijarro C., Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int. 2001, 59:415-424.
25. Romzova M., Hohenadel D., Kolostova K., Pinterova D., Fojtikova M., Ruzickova S., Dostal C., Bosak V., Rychlik I., Cerna M. NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. Hum. Immunol. 2006, 67:706-713.
26. Liu W., Zhang X., Liu P., Shen X., Lan T., Li W., Jiang Q., Xie X., Huang H. Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. Eur. J. Pharmacol. 2010, 638:150-155.
27. Murphy M., Crean J., Brazil D.P., Sadlier D., Martin F., Godson C. Regulation and consequences of differential gene expression in diabetic kidney disease. Biochem. Soc. Trans. 2008, 36:941-945.
28. Lan Y., Zhou Q., Wu Z.L. NF-kappa B involved in transcription enhancement of TGF-beta 1 induced by Ox-LDL in rat mesangial cells. Chin. Med. J. 2004, 117:225-230.
29. Yang W.S., Chang J.W., Han N.J., Lee S.K., Park S.K. Spleen tyrosine kinase mediates high glucose-induced transforming growth factor-beta1 up-regulation in proximal tubular epithelial cells. Exp. Cell Res. 2012, 318:1867-1876.
30. Hills C.E., Squires P.E. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am. J. Nephrol. 2010, 31:68-74.
31. Raptis A.E., Viberti G. Pathogenesis of diabetic nephropathy. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2):S424-S437.
32. Wang J., Huang H., Liu P., Tang F., Qin J., Huang W., Chen F., Guo F., Liu W., Yang B. Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur. J. Pharmacol. 2006, 553:297-303.